Optimi Health (OPTH) said Wednesday it has completed its first export of naturally derived psilocybin to the UK to support a planned phase 2 clinical trial for patients with treatment-resistant depression.
The pharmaceutical company said the shipment includes psilocybin biomass and finished 5mg psilocybin capsules.
Price: $4.92, Change: $+0.06, Percent Change: +1.19%